REGN — REGENERON PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 872589 ·
Last close
$734.81
Market Cap
$74.32B
52W High
$859.34
52W Low
$538.24
ADV30
723,740
Next earnings
2026-10-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 4,290,700,000 | 3,714,200,000 | 1,420,500,000 | 1,296,900,000 | 41,730,600,000 | 2,455,800,000 | 10,019,200,000 |
| Mar 2026 | 3,605,400,000 | 2,936,000,000 | 744,800,000 | 727,200,000 | 40,868,800,000 | 2,962,600,000 | 9,445,200,000 |
| Dec 2025 | 3,884,300,000 | 3,299,700,000 | 898,600,000 | 844,600,000 | 40,558,700,000 | 3,118,100,000 | 9,301,800,000 |
| Sep 2025 | 3,754,300,000 | 3,232,700,000 | 1,109,900,000 | 1,460,000,000 | 40,169,400,000 | 2,506,400,000 | 9,211,600,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$4,681,300,000
Investing CF
$-704,200,000
Financing CF
$-3,524,800,000
CapEx
$-1,106,100,000
Dividends Paid
$-378,500,000
Buybacks
$-3,902,400,000
EPS Diluted TTM
$40.46
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$37,621,400,000
Inventory
$3,084,300,000
Receivables
$6,565,400,000
ST Investments
$5,538,800,000
EBIT TTM
$5,221,400,000
Pretax Income TTM
$5,166,000,000
Interest Exp TTM
$55,400,000
Analysts
27
Yahoo Snapshot (yfinance, live)
Total Revenue
$15,534,699,520
EBITDA
$4,702,400,000
Free Cash Flow
$3,065,299,968
Enterprise Value
$72,747,671,552
Total Cash
$7,994,599,936
Total Debt
$2,706,599,936
Shares Out
101,137,842
Trailing EPS
$40.40
Book Value
$316.11
ROE
14.0%
ROA
6.5%
Div Yield
0.48%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 14,342,900,000 | 3,702,000,000 | 4,504,900,000 | 40,558,700,000 | 9,301,800,000 | 31,256,900,000 | 4,978,900,000 |
| Dec 2024 | 14,202,000,000 | 3,990,700,000 | 4,412,600,000 | 37,759,400,000 | 8,405,800,000 | 29,353,600,000 | 4,420,500,000 |
| Dec 2023 | 13,117,200,000 | 4,047,100,000 | 3,953,600,000 | 33,080,200,000 | 7,107,100,000 | 25,973,100,000 | 4,594,000,000 |
| Dec 2022 | 12,172,900,000 | 4,738,900,000 | 4,338,400,000 | 29,214,500,000 | 6,550,500,000 | 22,664,000,000 | 5,014,900,000 |
TTM Snapshot
Revenues TTM
$6,749,400,000
NetIncome TTM
$2,149,300,000
OpCashFlow TTM
$0
Assets (Latest)
$40,558,700,000
Forward EPS
$60.62
Max Pain — expiry 2026-12-18
max pain strike: $950.00 · spot: $734.81 · call oi: 826 · put oi: 442
Expected Move to 2026-12-18:
±$61.48
(8.37%) —
implied range
$673.33 –
$796.29
· ATM straddle on $730.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GSK | GSK plc | $94.49B | $47.18 | — |
| TAK | TAKEDA PHARMACEUTICAL CO LTD | $57.04B | $17.86 | — |
| SNY | Sanofi | $97.45B | $40.67 | — |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $45.81B | $39.31 | — |
| NVO | NOVO NORDISK A S | $125.07B | $37.40 | — |
News headlines (Yahoo Finance, 1h cache)
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
2026-10-01 15:35 · Yahoo
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
2026-10-01 15:30 · Yahoo
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion
2026-10-01 15:02 · Yahoo
Sanofi, Regeneron to Expand Alliance in Up to $8 Billion Deal
2026-10-01 14:48 · Yahoo
Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion
2026-10-01 14:03 · Yahoo
Sanofi and Regeneron expand immunology partnership to the tune of $8bn
2026-10-01 11:40 · Yahoo
Regeneron, Sanofi Expand Immunology Alliance With $1B Upfront Payment: Here Are The Key Highlights
2026-10-01 11:36 · Yahoo
Sanofi gains after expanding Regeneron partnership with $8 billion deal
2026-10-01 06:00 · Yahoo
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
2026-10-01 05:00 · Yahoo
OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD
2026-10-01 21:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.